239 related articles for article (PubMed ID: 28712170)
1. Characteristics And Outcomes Of Anaplastic Large Cell Lymphoma Patients-A Single Centre Experience.
Athar S; Siddiqui N; Hameed A
J Ayub Med Coll Abbottabad; 2017; 29(1):37-41. PubMed ID: 28712170
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic large cell lymphoma: a single institution experience from India.
Lakshmaiah KC; Guruprasad B; Shah A; Kavitha S; Abraham LJ; Govindbabu K; Aruna Kumari BS; Appaji L
J Cancer Res Ther; 2013; 9(4):649-52. PubMed ID: 24518711
[TBL] [Abstract][Full Text] [Related]
5. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
6. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.
Sibon D; Fournier M; Brière J; Lamant L; Haioun C; Coiffier B; Bologna S; Morel P; Gabarre J; Hermine O; Sonet A; Gisselbrecht C; Delsol G; Gaulard P; Tilly H
J Clin Oncol; 2012 Nov; 30(32):3939-46. PubMed ID: 23045585
[TBL] [Abstract][Full Text] [Related]
10. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathological relevance of uniform CD56 expression in anaplastic large cell lymphoma: a retrospective analysis of 18 cases.
Yu BH; Zhang Y; Xue T; Shui RH; Lu HF; Zhou XY; Zhu XZ; Li XQ
Diagn Pathol; 2021 Jan; 16(1):1. PubMed ID: 33402163
[TBL] [Abstract][Full Text] [Related]
12. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R; Falini B; Chott A; Meijer CJ
J Clin Pathol; 2000 Jun; 53(6):445-50. PubMed ID: 10911802
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
Wang X; Wu J; Zhang M
Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A; Soma L
Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
[TBL] [Abstract][Full Text] [Related]
15. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
[TBL] [Abstract][Full Text] [Related]
17. Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center.
Park SJ; Kim S; Lee DH; Jeong YP; Bae Y; Han EM; Huh J; Suh C
Yonsei Med J; 2008 Aug; 49(4):601-9. PubMed ID: 18729302
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
19. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
20. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
Cederleuf H; Bjerregård Pedersen M; Jerkeman M; Relander T; d'Amore F; Ellin F
Br J Haematol; 2017 Sep; 178(5):739-746. PubMed ID: 28485010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
